drugset / Trial / NCT01900795

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

NCT01900795

Phase 2 Terminated 114 enrolled Purdue Pharma LP
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to assess the analgesic properties of an oral dose of V117957 4.5 mg aqueous suspension in the third molar extraction model

Timeline

Start
2013-07
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ibuprofen Small molecule 400 mg Oral
Subject Sunobinop Small molecule 4.5 mg Oral

Indications

No indication recorded.